The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study
We found that no matter CDK4/6i or EVE was used first, the survival were not significantly different between Group A and Group B. Both can be clinical options.
Authors
- Binghe Xu (ORCID: https://orcid.org/0000-0003-4195-337X)
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Hanfang Jiang (ORCID: https://orcid.org/0000-0002-3502-7073)
- Weihong Zhao (ORCID: https://orcid.org/0000-0002-9645-7499)
- Yujing Tan (ORCID: https://orcid.org/0000-0003-3256-2764)
- Ying Fan (ORCID: https://orcid.org/0000-0002-2925-507X)
- Yuqian Liao (ORCID: https://orcid.org/0000-0003-3055-893X)
- Bo Lan (ORCID: https://orcid.org/0000-0002-2962-439X)
- Qing Li (ORCID: https://orcid.org/0000-0002-4191-9596)
- Shanshan Chen (ORCID: https://orcid.org/0000-0002-9944-6429)
- Yang Luo (ORCID: https://orcid.org/0000-0002-5501-9935)
- Pin Zhang (ORCID: https://orcid.org/0000-0001-8903-3666)
- Qiao Li (ORCID: https://orcid.org/0000-0002-9714-198X)
- Jiayu Wang (ORCID: https://orcid.org/0000-0002-5608-0738)
- Yipeng Li (ORCID: https://orcid.org/0000-0001-9099-4077)
Institutions
- Nanchang University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Chinese PLA General Hospital (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Ministry of Education (ET)
- Zhengzhou People's Hospital (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e38147
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Chinese Academy of Medical Sciences
- Wu Jieping Medical Foundation